Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial

Autor:	Rescigno, Pasquale, Porta, Nuria, Finneran, Laura, Riisnaes, Ruth, Figueiredo, Ines, Carreira, Suzanne, Flohr, Penny, Miranda, Susana, Bertan, Claudia, Ferreira, Ana, Crespo, Mateus, Rodrigues, Daniel Nava, Gurel, Bora, Nobes, Jenny, Crabb, Simon, Malik, Zafar, Ralph, Christy, McGovern, Ursula, Hoskin, Peter, Jones, Robert J., Birtle, Alison, Gale, Joanna, Sankey, Peter, Jain, Suneil, McLaren, Duncan, Chadwick, Eliot, Espinasse, Aude, Hall, Emma, de Bono, Johann
Zdroj:	In European Journal of Cancer July 2024 205
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect